TRIUMPH: 58% of acute severe UC patients responded ‘within 2 days’ of starting Xeljanz

WASHINGTON — Nearly 60% of patients with acute severe ulcerative colitis responded to Xeljanz 10 mg twice daily by day 7, with one-third of patients in steroid-free remission by 6 months, according to interim analysis data presented here.
“There are few recommended therapies for acute severe UC management given the need for rapidly acting therapies,” Neeraj Narula, MD, MPH, FRCPC, director of the IBD Clinic at Hamilton Health Sciences and associate professor of medicine at McMaster University, told Healio. “Patients with prior anti-TNF failure who present with acute

WASHINGTON — Nearly 60% of patients with acute severe ulcerative colitis responded to Xeljanz 10 mg twice daily by day 7, with one-third of patients in steroid-free remission by 6 months, according to interim analysis data presented here.
“There are few recommended therapies for acute severe UC management given the need for rapidly acting therapies,” Neeraj Narula, MD, MPH, FRCPC, director of the IBD Clinic at Hamilton Health Sciences and associate professor of medicine at McMaster University, told Healio. “Patients with prior anti-TNF failure who present with acute